Dh’fhaodadh ìre theophylline de 5–15 mg/L a bhith na thargaid làimhseachaidh iomchaidh, ach chan eil toradh sam bith a’ gealltainn sàbhailteachd. Bidh àm an dòis, an cruth-leigheis, na comharraidhean agus atharrachaidhean o chionn ghoirid ann an smocadh no cungaidhean-leigheis a’ dearbhadh dè tha an àireamh agad a’ ciallachadh.
Prìomh phuingean
- Targaid làimhseachaidh: Bidh mòran luchd-clionaigeach a’ cleachdadh 5–15 mg/L, ged a tha cuid de dh’obair-lannan a’ liostadh 10–20 mg/L; tha prìomhachas aig targaid an neach-òrdachaidh agad.
- Toradh àrd: Tha ìre theophylline os cionn 20 mg/L a’ meudachadh dragh mu phuinnseanachadh agus feumar comhairle clionaigeach fhaighinn gu sgiobalta.
- Tha comharraidhean a’ faighinn prìomhachas seach an raon: Faodaidh cur a-mach leantainneach, buille-cridhe luath no neo-riaghailteach, troimh-chèile no glacaidh puinnseanachadh a chomharrachadh fiù ’s fo 20 mg/L.
- Aonadan: Tha 1 mg/L co-ionann ri 1 µg/mL; iomadaich mg/L le mu 5.55 gus tionndadh gu µmol/L.
- Àm an t-sampaill: Tha amannan as àirde eadar-dhealaichte aig toraidhean sa bhad agus toraidhean le sgaoileadh atharraichte; chan urrainnear ìre an t-seisein a choimeas gu fèin-obrachail ri targaid na h-ìre as àirde.
- Sgur de smocadh: Faodaidh sgur de smocadh fuadach teophylline a lùghdachadh gu mòr taobh a-staigh mu sheachdain, fiù ’s nuair a thathar a’ cleachdadh stuthan eilein nicotine.
- Fiabhras: Faodaidh teòthachd sheasmhach mu 39°C airson co-dhiù 24 uair fuadach a dhèanamh nas slaodaiche agus an ìre àrdachadh le dòs nach deach atharrachadh.
- Eadar-obrachaidhean: Faodaidh ciprofloxacin, fluvoxamine, cimetidine agus cuid de dh’antaibheotaicean macrolide dùmhlachdan teophylline àrdachadh.
- Gnìomh èiginneach: Faigh cùram èiginneach ma thachras grèim, tuiteam, troimh-chèile mhòr no buille-cridhe luath no neo-riaghailteach a mhaireas; na fuirich ri toradh ìre eile.
Dè an ìre theophylline a thathar a’ meas sàbhailte?
A ìre teophylline de 5–15 mg/L na thargaid leigheis a thathar a’ cleachdadh gu cumanta, agus tha cuid de dh’obair-lannan ag aithris 10–20 mg/L. Tha puinnseanta nas dualtaiche os cionn 20 mg/L, ach faodaidh comharraidhean nochdadh taobh a-staigh an raoin ainmichte; tha targaid an lighiche agus àm an t-sampaill nas cudromaiche na bratach na h-obair-lann leis fhèin.
Tha raon teirpeach caol aig teophylline, a’ ciallachadh gu bheil am beàrn eadar dùmhlachd fheumail agus dùmhlachd chronail an ìre mhath beag. Dh’fhaodadh toradh 14 mg/L a bhith freagarrach do phlana leigheis aon neach ach a bhith ro àrd gun fheum do neach eile aig a bheil smachd iomchaidh air comharraidhean aig 7 mg/L, gu h-àraidh ma tha droch bhuaidhean no fuadach lùghdaichte ann.
Chan eil dùmhlachdan nas àirde a’ ciallachadh gu fèin-obrachail gu bheil an leigheas analach nas fheàrr. Tha lèirmheas Barnes anns an American Journal of Respiratory and Critical Care Medicine a’ mìneachadh an dà chuid buaidhean leudachaidh nam bronchi agus dòighean a thathar a’ moladh airson buaidh an-aghaidh sèid aig dùmhlachdan nas ìsle, ach chan eil iad sin nan amasan leigheis eadar-mhalairteach (Barnes, 2013). Chan eil buaidh bith-eòlach a thathar a’ moladh aig 1–5 mg/L na adhbhar airson dòs òrdaichte àrdachadh no lùghdachadh gun mheasadh air a’ bhuannachd chlionaigeach fhèin.
’S e anailisiche deuchainnean fala AI a th’ ann an Kantesti a chuidicheas le mìneachadh carson a tha feum air eachdraidh dòsachaidh, chan e dìreach bratach uaine na h-obair-lann, nuair a tha toradh teophylline 12 mg/L ann. Bidh sinn a’ toirt seachad mìneachadh foghlaim seach co-dhùnaidhean òrdachaidh; tha na buidheann agus adhbhar a’ mìneachadh an eadar-dhealachaidh sin. Thoir an toradh, dearbh ainm an leigheis, àm an dòs mu dheireadh agus comharraidhean o chionn ghoirid don sgioba òrdachaidh.
Mar a leughas tu an raon therapach theophylline agus na h-aonadan
An raon teirpeach teophylline a’ mìneachadh nochdadh ris an druga a thathar an dùil, chan e luach àbhaisteach do neach nach eil a’ faighinn leigheis. Tha 1 mg/L co-ionann ri 1 µg/mL, agus tha toradh ann an µmol/L mu 5.55 uiread na h-aon dùmhlachd ann an mg/L.
Tha dùmhlachd 10 mg/L mu 55.5 µmol/L, while 20 mg/L is approximately 111 µmol/L. Check the units before comparing reports from different countries, because a number such as 83 may represent approximately 15 mg/L rather than an extreme overdose. A therapeutic range also assumes a particular sampling approach, which may not be printed beside the result.
A laboratory upper limit of 20 mg/L is not an instruction to aim for 20 mg/L. NICE’s COPD guideline recommends plasma-level and interaction monitoring when theophylline is used, with particular caution in older people and during relevant antibiotic treatment (NICE, 2018). Similar distinctions between laboratory ranges and individualized targets appear in our guide to digoxin targets and timing.
Results between 15 and 20 mg/L deserve context rather than automatic reassurance or an automatic toxicity diagnosis. For a hypothetical person whose agreed target is 5–10 mg/L, a reading of 18 mg/L is above their treatment goal despite falling within a printed 10–20 mg/L interval. Ask whether the range applies to a peak, trough or other timed sample before interpreting the color coding.
| Ìre | Raon | Na tha e a’ ciallachadh |
|---|---|---|
| Common lower treatment target | 5–15 mg/L | Often suitable when clinical benefit is adequate; safety still depends on symptoms, timing and individual risk. |
| Upper part of some laboratory ranges | >15–20 mg/L | May exceed the clinician’s target; review adverse effects and whether the sample was correctly timed. |
| Above the usual upper boundary | >20–30 mg/L | Increased toxicity concern; obtain prompt clinical advice, with urgent assessment if symptoms are present. |
| Àrdachadh gu mòr | >30 mg/L | Urgent clinical assessment is needed, especially with chronic exposure; serious toxicity depends on symptoms and exposure pattern. |
Cuin a bu chòir sampall theophylline a ghabhail?
A theophylline sample must be timed to the specific product and monitoring question. Immediate-release oral products often peak around 1–2 hours, whereas some modified-release monitoring protocols use samples 4–6 hours after dosing; these windows are not interchangeable.
A trough sample is collected just before the next scheduled dose, but theophylline monitoring is not always based on troughs. A low predose result may coexist with a substantially higher postdose peak, so increasing treatment solely because a trough is below a peak-based 10–20 mg/L range can be unsafe. The laboratory request should state what the prescriber intends to measure.
A result of 9 mg/L collected 2 hours after a dose cannot be compared directly with 9 mg/L collected 12 hours after a dose. Kantesti can help organize the reported concentration alongside supplied timing details, but missing dose times remain missing information. Our explanation of peak and trough sampling illustrates the principle, although gentamicin’s timing rules must not be transferred to theophylline.
Suspected toxicity requires immediate sampling rather than waiting for a scheduled peak or trough. If symptoms develop 3 hours after an extra dose, clinicians need that history and may arrange serial concentrations because absorption can continue. Write down actual times, not simply “morning” or “after tablets,” and do not delay urgent care to produce a more neatly timed result.
Carson a tha cruth-leigheis agus staid sheasmhach ag atharrachadh an toraidh
Immediate-release, twice-daily modified-release and once-daily theophylline products can produce different concentration patterns. A level is most interpretable after a stable regimen has reached stàite stèidhichte, commonly assessed after about 3 latha, although slower clearance can require longer.
A three-day interval is a monitoring convention, not a guarantee that every person has stabilized. With a hypothetical half-life of 8 hours, five half-lives take about 40 hours; with a half-life of 24 hours, they take about 5 days. Fever, liver impairment and heart failure can extend that interval, so an early result may underestimate the eventual concentration on the same dose.
Changing a modified-release brand can change the shape of the concentration curve even when the daily milligram dose is unchanged. Food effects and peak timing differ between products, including some once-daily preparations whose peaks occur later than 4–6 hours. The broader lesson resembles formulation-specific drug monitoring, but each medicine needs its own product-specific instructions.
Modified-release tablets should not be crushed unless the product information explicitly permits the intended method of administration. For example, a prescribed 200 mg tablet may have a score line without being suitable for crushing, and destroying a release mechanism can increase early exposure. Keep the box or a photograph of its exact name available, especially after a pharmacy substitution, hospital discharge or change in dosing schedule.
Dè na comharraidhean puinnseanachaidh theophylline a dh’fheumas cùram èiginneach?
Theophylline toxicity symptoms include nausea, repeated vomiting, tremor, restlessness, insomnia and a rapid heartbeat. Seizures, collapse, severe confusion or a sustained rapid or irregular heartbeat require emergency care, even if a previous theophylline level was below 20 mg/L.
Persistent vomiting with a racing heartbeat is more concerning than either symptom considered alone in someone taking theophylline. Both can reflect excessive drug effect, while vomiting also disrupts fluid and electrolyte balance. A hypothetical pulse of 125 beats per minute accompanied by repeated vomiting should not be dismissed as anxiety simply because yesterday’s concentration was 16 mg/L.
Theophylline and inhaled beta-agonists can both cause tremor and palpitations, making symptom attribution difficult without assessment. Potassium, magnesium, an ECG and the current level may help distinguish medication effects from other causes; our stiùireadh deuchainn palpitations explains why a concentration alone is insufficient. A pulse above 100 beats per minute is not itself a toxicity diagnosis, but a new sustained change deserves attention.
If toxicity is suspected, do not take another theophylline dose while obtaining urgent medical advice. Seek emergency help immediately for a seizure, collapse or severe cardiac symptoms rather than waiting 1–2 hours for a routine service to respond. Do not induce vomiting or take activated charcoal at home; bring the medicine packaging and details of all doses, including any accidentally repeated tablets.
Am faod puinnseanachadh tachairt taobh a-staigh raon an obair-lann?
Theophylline toxicity can occur within a laboratory’s 10–20 mg/L range because susceptibility, sampling time and protein binding vary. A total concentration of 17 mg/L does not exclude an earlier higher peak or an unusually large proportion of active, unbound drug.
Routine theophylline assays usually measure total drug, including both protein-bound and unbound fractions. Approximately 40% is normally protein bound, but binding can decrease in circumstances such as cirrhosis, acidemia or late pregnancy. Our albumin agus pròtain againn a’ stiùireadh helps explain the context, although albumin alone cannot reliably calculate an individual free theophylline concentration.
A free theophylline measurement may help when symptoms conflict with the total result. Product labeling describes an unbound therapeutic interval of approximately 6–12 mg/L, but this is not a routine target for every patient or a conversion formula. For a hypothetical total result of 15 mg/L with reduced binding, a clinician may request the free fraction instead of assuming that the laboratory’s total-drug interval establishes safety.
Kantesti is an AI blood test interpretation platform that explains why a symptomatic result of 17 mg/L deserves clinical review rather than automatic reassurance. Ar an dòigh-obrach airson dearbhadh clionaigeach describes the distinction between interpretation and a prescribing decision. People over 60 years, those with neurological disease and those with hypoxia may be more vulnerable, but no single age or albumin cutoff predicts all adverse effects.
Mar a dh’fhaodas sgur de smocadh ìre theophylline àrdachadh
Stopping smoking can raise theophylline concentrations on an unchanged dose because tobacco smoke induces enzymes that clear the medicine. US product labeling reports an approximately 40% reduction in clearance after 1 week of abstinence, although the individual change varies.
Nicotine is not the main driver of the smoking–theophylline interaction. Combustion-related chemicals induce CYP1A2, so nicotine patches, gum or switching away from cigarettes do not reliably preserve the previous clearance rate. A cotinine result and nicotine exposure can document nicotine use, but it cannot establish whether theophylline-metabolizing enzyme induction remains unchanged after 7 smoke-free days.
A reduction in clearance can produce a larger concentration rise than the percentage initially suggests. In a deliberately simplified example, a stable concentration of 10 mg/L with clearance falling to 60% of its previous value would become approximately 16.7 mg/L if dose, absorption and other factors stayed constant. Actual theophylline kinetics can be nonlinear, so this calculation explains the risk rather than providing a dose-adjustment rule.
Smoking cessation should be supported, not discouraged because of theophylline monitoring. Tell the prescribing team when smoking stops, substantially decreases or restarts, and ask for an early reassessment plan rather than waiting for the next annual review. Kantesti can help place two dated results alongside a recorded smoking change, but clinicians must decide whether a dose reduction and repeat level within several days are appropriate.
Carson a dh’fhaodas fiabhras agus tinneas geur an ìre àrdachadh
Sustained fever can slow theophylline clearance and raise the level without any dose increase. Product labeling highlights temperatures around 39°C lasting at least 24 hours as a meaningful warning pattern, but lower prolonged fevers and severe illness can also matter.
Fever-related accumulation can be mistaken for worsening respiratory illness. Nausea, poor sleep and tachycardia may be attributed to a chest illness even when theophylline contributes, particularly after 2–3 days of reduced clearance. Record the highest temperature, its duration, fluid intake and whether the regular tablets continued; these details can explain a rising result more usefully than a single inflammatory marker.
CRP and white-cell counts do not measure theophylline clearance. A person may need a drug level despite only modest changes in either test, while an elevated CRP does not prove that a concentration of 18 mg/L is toxic. Our explanation of eas-aonta WBC agus CRP shows why illness severity cannot be reduced to one laboratory result.
Illness and its treatment can create two simultaneous reasons for accumulation. In a hypothetical case, a 39.2°C fever persisting for 30 hours plus newly prescribed ciprofloxacin warrants contact with the prescribing team even if the last stable level was 8 mg/L. Do not wait for the next scheduled monitoring appointment when new vomiting, tremor or palpitations accompany that combination.
Dè na cungaidhean-leigheis a dh’fhaodas ìre theophylline àrd adhbharachadh?
Ciprofloxacin, fluvoxamine, cimetidine and some macrolide antibiotics can raise theophylline levels by reducing clearance. The effect is drug-specific: 1 antibiotic cannot be assumed equivalent to another, and stopping an enzyme-inducing medicine can also cause accumulation.
Erythromycin and clarithromycin can interact with theophylline, while azithromycin generally has much less effect on its clearance. Ciprofloxacin is a recognized concern, but fluoroquinolones are not all identical in this respect. NICE specifically advises reducing theophylline dosage when interacting macrolide or fluoroquinolone antibiotics are prescribed for COPD exacerbations; the prescriber determines the change and monitoring, not a universal percentage applied at home.
Starting a strong inhibitor is not the only interaction scenario. Stopping rifampicin, carbamazepine or phenytoin can remove an enzyme-inducing effect and allow a previously tolerated dose to produce higher concentrations over subsequent days. Some of the same smoking and CYP1A2 issues arise in clozapine medication safety, although the relevant tests and treatment thresholds differ.
A complete medication review should include nonprescription products and recently discontinued medicines. Cimetidine bought for indigestion can be relevant even if the regular prescription list has not changed, and a 3-day antibiotic course can overlap with the start of accumulating drug. Ask a pharmacist to check the exact medicine names, including herbal products, and arrange repeat levels according to the expected interaction rather than the package color or drug class alone.
Mar a tha aois, galar grùthan agus fàilligeadh cridhe a’ toirt buaidh air fuadachadh
Older age, significant liver disease and congestive heart failure can reduce theophylline clearance. Product labeling describes reductions of 50% no barrachd in some patients with liver impairment or heart failure, making an unchanged dose potentially excessive after health status changes.
Theophylline is mainly metabolized by the liver in adults, so a normal creatinine result does not establish normal drug clearance. This differs from medicines whose elimination is predominantly renal; our stiùireadh againn air mìneachadh gnìomh nan dubhagan explains what creatinine does and does not measure. Only a relatively small fraction, roughly 10%, is excreted unchanged in adult urine, although newborn physiology differs substantially.
Normal ALT and AST values cannot rule out reduced theophylline metabolism. Heart failure, hepatic congestion and changes in liver functional reserve can affect clearance without a proportionate rise in routine enzyme tests. In a hypothetical adult with worsening edema, breathlessness and a rise from 9 to 18 mg/L on the same dose, the relevant question is what changed physiologically—not whether the tablet count remained correct.
Adults over 60 years often need more cautious dosing and review, particularly when frailty, hypoxia or multiple interacting medicines coexist. Our guide to buaidhean cungaidh-leigheis ann an seann daoine explains why a previously tolerated regimen can become unsuitable. Age is a risk modifier rather than a stand-alone dose formula; children, pregnancy and neonatal use require separate specialist interpretation rather than applying an adult 5–15 mg/L target indiscriminately.
Na tha ìre ìosal a’ ciallachadh—agus mar a dh’atharraicheas caffeine cùisean
A low theophylline level does not automatically require a higher dose. Toradh fo 5 mg/L may reflect sampling time, missed doses, faster clearance or an intentionally low target; caffeine can worsen tremor and palpitations without necessarily explaining the measured concentration.
Clinical benefit determines whether a low concentration is a problem. A correctly timed result of 4 mg/L in someone with good control may need a treatment review rather than automatic escalation, whereas the same result with worsening breathlessness requires assessment of the whole respiratory regimen. Check adherence and technique for other prescribed treatments before assuming that raising theophylline will provide the missing benefit.
Coffee, strong tea, energy drinks and cocoa add methylxanthine exposure, which can compound insomnia, tremor or palpitations. Approximately 80–100 mg of caffeine in a typical cup of brewed coffee is a useful reference, but portions and preparations vary widely. Unlike an overdose assessment described in our salicylate level timing guide, a caffeine history does not replace measurement of the prescribed drug.
Missed doses should not be corrected by doubling the next dose unless the prescriber has explicitly instructed it. For a hypothetical twice-daily regimen, taking two 200 mg doses together can create a different peak from taking them 12 hours apart, even when the daily total appears unchanged. Keep caffeine intake reasonably consistent, follow the medicine’s missed-dose instructions and never use extra fluids, food or supplements as a home treatment for suspected toxicity.
Dè thachras às dèidh ìre theophylline àrd?
A high theophylline level requires assessment of symptoms, exposure pattern and whether the concentration is rising. Results above 20 mg/L warrant prompt clinical advice; markedly elevated levels or significant symptoms need urgent hospital assessment, with treatment guided by more than the number.
Acute overdose and chronic accumulation have different risk patterns. An older adult accumulating drug over several days may develop serious toxicity at a lower concentration than a younger person after a single ingestion, so a universal “danger starts here” cutoff is misleading. A result above 30 mg/L during regular treatment is especially concerning, and a recent extra modified-release dose can make an early measurement underestimate the eventual peak.
Hospital assessment commonly includes serial theophylline levels, an ECG, potassium, magnesium, glucose and acid–base evaluation. Activated charcoal may be used under medical supervision, sometimes in repeated doses, but suitability depends on airway protection and other risks. The general need to interpret ingestion time resembles overdose sampling decisions; however, the acetaminophen nomogram must never be applied to theophylline.
EXTRIP recommends extracorporeal treatment for severe theophylline poisoning, including an acute concentration above 100 mg/L or severe manifestations such as seizures, life-threatening arrhythmias or shock (Ghannoum et al., 2015). The workgroup also suggests treatment in chronic poisoning above 60 mg/L, with additional lower-threshold considerations for vulnerable age groups. These are specialist treatment criteria—not concentrations below which home observation is automatically safe.
Mar a nì thu coimeas eadar toraidhean agus planadh deuchainn ath-aithris fheumail
Two theophylline results are comparable only when dose, formulation and sampling conditions are sufficiently similar. Atharrachadh bho 8 to 14 mg/L may represent real accumulation, a later peak sample or both; repeat testing should answer a specific clinical question.
Consider a hypothetical 58-year-old taking 200 mg of modified-release theophylline every 12 hours. A level of 8 mg/L drawn immediately before a dose and a later level of 14 mg/L drawn 5 hours afterward cannot establish worsening clearance by themselves. The practical next step is to confirm the intended sampling window and repeat under the prescriber’s instructions, unless symptoms require immediate assessment instead.
Now consider a different hypothetical person whose comparable levels rise from 10 to 18 mg/L after 7 days without cigarettes. The unchanged formulation and matched dose-to-sample interval make reduced clearance a stronger explanation, especially if nausea has appeared. Our stiùireadh gluasaid sàbhailteachd cungaidh-leigheis explains why the timeline of smoking, fever and prescription changes belongs beside the laboratory trend.
Kantesti is an AI-powered blood test analysis tool that can help organize a 10-to-18 mg/L trend alongside the history you provide. Ar modh-obrach mìneachaidh AI explains how supplied context supports interpretation without replacing clinician oversight. Before a repeat test, confirm five details: exact product, dose schedule, last-dose time, sample time and relevant changes; after an intervention, the prescriber chooses when the new level will be informative.
Foillseachaidhean rannsachaidh agus crìochan eadar-mhìneachaidh AI
Theophylline interpretation rests on pharmacology, product-specific monitoring and clinical assessment—not an AI-generated safe cutoff. A total result of 12 mg/L can be useful evidence, but published ranges and automated explanations cannot exclude toxicity in a symptomatic person.
The evidence supports different roles for theophylline at different concentrations, but a biological mechanism is not the same as proven benefit for every treatment strategy. Barnes’s 2013 review discusses proposed effects at lower levels alongside bronchodilation at higher exposure, while NICE’s 2018 COPD guidance emphasizes selective use and monitoring. Neither source establishes a universally safe 5–15 mg/L interval independent of symptoms, formulation and individual risk.
Extracorporeal-treatment thresholds address severe poisoning rather than routine therapeutic monitoring. Ghannoum and colleagues’ EXTRIP review uses criteria such as an acute concentration above 100 mg/L, but its recommendations also respond to severe symptoms and the exposure pattern. Our guide to sgrùdadh a dhèanamh air mìneachaidhean meidigeach AI helps readers distinguish a hospital treatment threshold from a personal treatment target.
The two Kantesti publications listed below describe a validation framework and a global analysis report; they are not theophylline-specific trials or independent prescribing guidelines. They should not be cited as proof that an AI system can diagnose toxicity at 17 mg/L or safely change a dose. Our inbhean susbaint mheidigeach require that separation: use educational interpretation to prepare questions, and use the prescribing team or emergency services for clinical decisions.
Ceistean cumanta
Dè an raon leigheasach a th’ aig theophylline?
Mar as trice tha na targaidean airson làimhseachadh le theophylline taobh a-staigh 5–15 mg/L, ged a tha cuid de dh’obair-lannan ag aithris raon teirpeach de 10–20 mg/L. Faodaidh an neach-òrdachaidh targaid nas ìsle a thaghadh a rèir a’ bhuannachd, nam fo-bhuaidhean, na h-aoise agus tinneasan eile. Feumaidh àm an t-samplachaidh a bhith a rèir an toraidh agus a’ mhìneachaidh a thathar an dùil a dhèanamh air an ìre as àirde no as ìsle. Chan eil toradh taobh a-staigh raon an obair-lann a’ gealltainn sàbhailteachd.
A bheil ìre theophylline de 20 puinnseanta?
Tha ìre theophylline de 20 mg/L aig crìoch àrd mòran de na raointean obair-lann traidiseanta, agus tha puinnseanta nas coltaiche os cionn na dùmhlachd sin. Bidh fo-bhuaidhean aig cuid de dhaoine fo 20 mg/L, gu h-àraidh nuair a chruinnicheas e thar ùine no nuair a tha iad nas buailtiche dha. Mar sin, feumar toradh de 20 mg/L a sgrùdadh a rèir an targaid a shuidhich an clionaigear, àm na dòise agus nan comharraidhean. Tha feum air comhairle èiginneach ma tha cuir a-mach leantainneach, buille-cridhe rèisimeach no comharraidhean nearbhach ann, seach a bhith an urra ri fois-inntinn stèidhichte air an raon.
Cuin a bu chòir ìre theophylline a thomhas?
Tha an t-àm airson samplachadh theophylline an urra ris an fhoirmleachadh agus ri adhbhar an sgrùdaidh. Bidh toraidhean a thèid a leigeil ma sgaoil sa bhad gu tric a’ ruighinn an ìre as àirde mu 1–2 uair an dèidh dòs, agus bidh cuid de phròtacalan airson leigeil ma sgaoil atharraichte a’ cleachdadh sampall 4–6 uairean an dèidh na dòise. Feumaidh toraidhean eile amannan eadar-dhealaichte, agus thèid sampall aig an ìre as ìsle a ghabhail dìreach mus tèid an ath dhòs clàraichte a thoirt. Bu chòir amharas mu thocsaineachd a mheasadh sa bhad seach feitheamh ri uinneag samplachaidh àbhaisteach.
An urrainn do sgur de smocadh ìrean theophylline àrdachadh?
Faodaidh stad air smocadh ìrean theophylline àrdachadh, oir bidh ceò tombaca a’ brosnachadh nan einnseaman a tha an sàs ann a bhith a’ glanadh an stuth-leigheis. Tha bileagan an toraidh ag aithris lùghdachadh de mu 40% ann am fuadach às dèidh seachdain de staonadh, ged a tha na h-atharrachaidhean eadar-dhealaichte bho dhuine gu duine. Chan eil badan nicotine no guma nicotine a’ cur stad earbsach air an eadar-obrachadh seo, oir chan e nicotine prìomh adhbhar brosnachadh nan einnseaman. Inns don sgioba òrdachaidh nuair a stadas tu air smocadh, nuair a lùghdaicheas tu gu mòr e no nuair a thòisicheas tu às ùr, gus an urrainn dhaibh planadh a dhèanamh airson sgrùdadh agus atharrachadh dòs sam bith.
An urrainn do fhiabhras ìre theophylline àrdachadh?
Faodaidh fiabhras leantainneach ìre an theophylline àrdachadh le bhith a’ cur maill air fuadach an druga, fiù ’s nuair nach eil an dòs air atharrachadh. Tha teòthachd timcheall air 39°C a mhaireas co-dhiù 24 uair na phàtran rabhaidh aithnichte ann am fiosrachadh an toraidh, ach faodaidh tinneasan cudromach eile no tinneasan a mhaireas ùine mhòr a bhith buntainneach cuideachd. Dh’fhaodadh antibiotaicean a tha ag eadar-obrachadh leis an druga a’ bhuaidh a dhèanamh nas miosa rè tinneas analach. Bu chòir do chuideigin comhairle chlinigeach èiginneach iarraidh agus beachdachadh air ìre làithreach an druga ma nochdas cur a-mach, crith no palpaidean ùra.
Dè bu chòir dhomh a dhèanamh ma tha an ìre theophylline agam àrd?
Feumar comhairle clionaigeach fhaighinn gu sgiobalta ma tha ìre theophylline os cionn 20 mg/L, agus dh’fhaodadh gum bi feum air measadh èiginneach san ospadal ma tha an toradh gu math àrd no ma tha comharraidhean mòra ann. Faigh cùram èiginneach sa bhad ma thachras glacaidh, tuiteam às a chèile, troimh-chèile mhòr no buille-cridhe luath no neo-riaghailteach a mhaireas, ge bith dè an dùmhlachd a chaidh a thomhas. Ma tha amharas ann air puinnseanachadh, na gabh dòs eile de theophylline fhad ’s a tha thu a’ faighinn comhairle èiginneach. Na brosnaich cur a-mach, na cleachd làimhseachadh gual-fhiodha aig an taigh agus na obraich a-mach leat fhèin lùghdachadh dòs stèidhichte air toradh an obair-lann.
Faigh mìneachadh air na toraidhean deuchainn fala agad
Luchdaich suas aithisg an obair-lann agad agus mìnichidh AI Kantesti gach bith-chomharradh ann an cànan soilleir taobh a-staigh diogan. Air a chleachdadh le còrr is 2 mhillean neach air feadh an t-saoghail.
Tùsan
- Klein, T., Mitchell, S., & Weber, H. (2026). Frèam Dearbhaidh Clionaigeach v2.0 (Duilleag Dearbhaidh Meidigeach). Rannsachadh Meidigeach AI Kantesti. DOI
- Klein, T., Mitchell, S., & Weber, H. (2026). Neach-anailis Deuchainn Fala AI: 2.5M Deuchainnean air an Mion-sgrùdadh | Aithisg Slàinte Cruinne 2026. Rannsachadh Meidigeach AI Kantesti. DOI
- Barnes PJ (2013). Theophylline. American Journal of Respiratory and Critical Care Medicine. DOI
- National Institute for Health and Care Excellence (2018). Chronic obstructive pulmonary disease in over 16s: diagnosis and management. NICE Guideline NG115.
- Ghannoum M et al. (2015). Extracorporeal treatment for theophylline poisoning: systematic review and recommendations from the EXTRIP workgroup. Clinical Toxicology. DOI
- 2M+Deuchainnean air an sgrùdadh
- 127+Dùthchannan
- 100+Cànanan
Mu dheidhinn an sgioba mheidigeach
Comharran earbsa E-E-A-T
Eòlas
Lèirmheas clionaigeach air a stiùireadh le lighiche air sruthan-obrach mìneachaidh obair-lann.
Eòlas
Fòcas air leigheas obair-lann air mar a bhios bith-chomharraidhean (biomarkers) a’ giùlan ann an co-theacsa clionaigeach.
Ùghdarrasachd
Ath-sgrùdadh meidigeach leis an Dr Thomas Klein, le tabhartasan bhon Dr Sarah Mitchell agus an t-Oll. Dr Hans Weber.
Earbsachd
Mìneachadh stèidhichte air fianais le slighean leanmhainn soilleir gus dragh a lughdachadh.
Àicheadh meidigeach
Tha an artaigil seo dìreach airson adhbharan foghlaim agus chan eil e a’ dèanamh comhairle mheidigeach. Cuir fios an-còmhnaidh gu solaraiche cùram slàinte teisteanasach airson co-dhùnaidhean breithneachaidh is leigheis.
Foillsichte · Cuir fios chun sgioba dheasachaidh
Foillsichte le Kantesti Ltd, clàraichte ann an Sasainn agus sa Chuimrigh, àireamh companaidh. 17090423, Lunnainn, an Rìoghachd Aonaichte.
